Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Fabrizio

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Journal of the National Cancer Institute|April 1, 1974
Biologic characteristics of transformed rhesus foreskin cells infected with Mason-Pfizer monkey virusD L Fine, R J Peinta, L B Malan, et al.
Transplantation and Cellular Therapy|July 23, 2022
Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task ForceHannah-Lise T Schofield, Vanessa A Fabrizio, Suzanne Braniecki, et al.
Nature|December 19, 2008
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activityAndrew Xiao, Haitao Li, David Shechter, et al.
The Journal of Biological Chemistry|January 27, 2005
DRAGON, a bone morphogenetic protein co-receptorTarek A Samad, Anuradha Rebbapragada, Esther Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2021
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric NeoplasmsHimalee S Sabnis, David S Shulman, Benjamin Mizukawa, et al.
Bone Marrow Transplantation|May 12, 2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplantVanessa A Fabrizio, Nancy A Kernan, Farid Boulad, et al.
Journal of Gastrointestinal Oncology|August 29, 2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibitionDavid A Fabrizio, Thomas J George, Richard F Dunne, et al.
Nature Medicine|April 15, 2022
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialEdward S Kim, Vamsidhar Velcheti, Tarek Mekhail, et al.
The Journal of Molecular Diagnostics : JMD|August 25, 2019
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient SamplesSally E Trabucco, Kyle Gowen, Sophia L Maund, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Journal of the National Cancer Institute|April 1, 1974
Biologic characteristics of transformed rhesus foreskin cells infected with Mason-Pfizer monkey virusD L Fine, R J Peinta, L B Malan, et al.
Transplantation and Cellular Therapy|July 23, 2022
Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task ForceHannah-Lise T Schofield, Vanessa A Fabrizio, Suzanne Braniecki, et al.
Nature|December 19, 2008
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activityAndrew Xiao, Haitao Li, David Shechter, et al.
The Journal of Biological Chemistry|January 27, 2005
DRAGON, a bone morphogenetic protein co-receptorTarek A Samad, Anuradha Rebbapragada, Esther Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2021
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric NeoplasmsHimalee S Sabnis, David S Shulman, Benjamin Mizukawa, et al.
Bone Marrow Transplantation|May 12, 2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplantVanessa A Fabrizio, Nancy A Kernan, Farid Boulad, et al.
Journal of Gastrointestinal Oncology|August 29, 2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibitionDavid A Fabrizio, Thomas J George, Richard F Dunne, et al.
Nature Medicine|April 15, 2022
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialEdward S Kim, Vamsidhar Velcheti, Tarek Mekhail, et al.
The Journal of Molecular Diagnostics : JMD|August 25, 2019
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient SamplesSally E Trabucco, Kyle Gowen, Sophia L Maund, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
Pageof 7